

## Speakers



### Gavin Giovannoni

Professor and Chair of Neurology, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Queen Mary University of London

Professor Giovannoni's research interests focus on clinical issues related to optimizing MS DMTs, Epstein-Barr virus as a possible cause of MS, defining the MS endophenotype, MS-related neurodegeneration, biomarkers, clinical outcome measures, clinical trials and immune tolerance strategies.



### Shibeshih Belachew

Neurologist and Senior Medical Director for MS Disease Area in Global Product Development Medical Affairs at Roche, Basel, Switzerland

Dr Belachew was Director of MS Franchise and Head of Medical Director's office for Biogen Region Europe and Canada. He also served as a Director of Global Neurology for the natalizumab programme in Cambridge, MA, USA.



### Tomas Kalincik

Associate Professor and Head, Clinical Outcomes Research Unit, University of Melbourne, Australia and Head of the MS and Neuroimmunology Service, Royal Melbourne Hospital, Australia

Assoc. Professor Kalincik's research interests span treatment outcomes in MS and neuromyelitis optica, individualized therapy, prognostics, epidemiology and utility of volumetric magnetic resonance imaging.



### Maria Pia Sormani

Professor of Biostatistics at the University of Genoa, Italy

Professor Sormani has collaborated for more than 10 years with the neuroimaging research unit at the S. Raffaele Hospital in Milan, studying the methodological issues related to the use of magnetic resonance imaging in MS



### Ari Green

Medical Director, University of California San Francisco Multiple Sclerosis Center, CA, USA and Director, University of California San Francisco Neurodiagnostics Center, CA, USA

Dr Green's research focuses on how MS affects the visual system and methods to track and predict the disease course.



### Carmen Tur

Locum Consultant Neurologist at Luton and Dunstable Hospital NHS Trust, UK

Dr Tur is interested in the evolution of brain cortical networks using cortical thickness over time in patients with a first attack of MS and in primary progressive MS.



### Sharmilee Gnanapavan

Consultant Neurologist at Barts Health and Princess Alexandra Hospital NHS Trust and Honorary Senior Clinical Lecturer in the Department of Neuroscience & Trauma, Queen Mary University of London, UK

Dr Gnanapavan's research focus is body fluid biomarkers, ranging from basic science through to translation work in clinical practice, including clinical trials.



### Bruce Trapp

Chairman of the Department of Neurosciences at the Lerner Research Institute, Cleveland Clinic, OH, USA

Professor Trapp's research investigates the causes of neurological disability in MS patients, cellular mechanisms of brain repair in neurodegenerative diseases, the molecular biology of myelination, and mechanisms of glial neuroprotection.



### James Sumowski

Associate Professor of Neurology at The Mount Sinai Hospital in New York, USA and a clinical neuropsychologist at the Corinne Goldsmith Dickinson Center for MS, New York

Assoc. Professor Sumowski's research focuses on cognition in people with MS, with a particular interest in identifying sources of reserve against cognitive decline in people with MS. His research group is working to advance the understanding and improvement of functional outcomes.



### Anneke Van Der Walt

Neurologist and Head of MS and Neuro-ophthalmology at Alfred Health in Melbourne, Australia

Assoc. Professor Van Der Walt's research interests include treatment of MS tremor, cerebellar dysfunction in MS and MS cognition. She has a keen interest in women's health in MS as well as symptom management in people with MS.



### Dawn Langdon

Professor of Neuropsychology and Director of Health and Medicine at Royal Holloway, University of London, UK

Professor Langdon's research includes how the risks and benefits of MS medication are best communicated to patients. Other interests include how employment relates to cognition in MS and the measurement of cerebellar function.



### Jiwon Oh

Assistant Professor of Medicine in the Division of Neurology at the University of Toronto, Ontario, Canada

Dr Oh's research focuses on developing advanced MRI techniques in the spinal cord and brain for use in clinical settings. She is leading the Canadian National Progression Cohort, a prospective cohort study investigating progression in MS.

Follow us on Twitter @triMSonline and #triMSonline for the latest news

We thank our platinum sponsors, Novartis Pharma AG and F. Hoffmann-La Roche, for supporting the development of the *triMS.online* platform.

*triMS.online* is an initiative run by Oxford Health Policy Forum, a not-for-profit community interest company registered in England and Wales (registration number: 10475240).